Novel pre-clinical results regarding OncoSec’s intratumoral electroporation platform were highlighted as Editor’s Pick in Molecular Cancer Research

Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO, June 24, 2022 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company…

Click here to view original post